Lowest Price Guaranteed From USD 5,899
Published
April 2021
Pages
242
View Count
10136
Example Insights
-thumb.PNG) |
 |
-thumb.PNG) |
 |
 |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
-thumb.PNG) |
 |
Report Description
Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. However, owing to concerns, such as off target toxicity and low specificity, associated with chemical moieties, and the need to shift from the one-size-fits-all approach to personalized medicine, a better class of pharmacological interventions was required. The first biologic, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Briefly, biologics offer several benefits, including target specificity, better therapeutic efficacy and, consequently, favorable safety profiles compared to conventional chemical-based drugs. Moreover, these molecules have also demonstrated the ability to access elusive biological targets and treat diseases that were previously considered undruggable. Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interventions were approved for the treatment of various disease indications in the US and Europe. Given the advantages they offer, biologics are in high demand for the treatment of different disease indications. It is a well-known fact that antibodies emerged as the major therapeutic breakthroughs and have seen significant success in the past two decades. There are other vast opportunities for biologics in the foreseeable future. This segment of healthcare industry is in the midst of numerous innovations; examples include antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapeutics, and cell and gene therapies. These developments have set the stage for significant disruption, creating more therapeutic targets and, ultimately, taking personalized healthcare to new and astounding heights.
Despite their complex and cost intensive manufacturing protocols, biopharmaceuticals (once approved) are highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion in a year); prominent examples include (as per decreasing revenues generated in 2020) Humira®, Keytruda®, Stelara®, Opdivo®, Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®. The aforementioned products together, generated sales worth close to USD 80 billion in 2020 alone. Although the patents protecting some of these blockbuster drugs have already expired, the sales of the original product have not been significantly impacted. For instances, there are multiple approved biosimilar versions of Abbvie’s Humira®, but the company reported annual global revenues worth around USD 19 billion from the sales of this drug alone. For several other top selling biologic drugs, patents covering the affiliated intellectual property are soon expected to expire, opening the market to competition from follow-on biologics. However, there are ways in which innovators can extend their marketing exclusivity, and delay the entry of biosimilars; popular product lifecycle management strategies include gaining marketing authorization (and exclusivity) in a new geography, proving therapeutic benefit for a different disease indication (than the one the product was originally cleared to treat), developing a new formulation of the drug, demonstrating therapeutic benefit in combination with another drug / therapy, and making the product available in a novel drug delivery device / system. In other words, companies that have developed blockbuster biologic products are expected to continue benefiting from their respective high-value assets in the short-mid term. However, we anticipate the market for such products to grow steadily and then plateau, before gradually declining over time, as impending patent expiries (including those that have been extended) pave way for biosimilars.
The “Top Selling Biologics Market, 2021-2030: Focus on Product Landscape Assessment, Ongoing Clinical Trials, Promotional Content Analysis, Other Life Cycle Management Strategies, Competition from Biosimilars, Annual Treatment Cost Comparison, Sales Evolution and Future Opportunity” report features an extensive study of the current market landscape and future potential of the top selling biologics available for the treatment of a variety of disease indications. The study includes an in-depth analysis, highlighting the key initiatives undertaken by various stakeholders engaged in this domain. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the existing market size and future growth potential within the top selling biologics market, over the coming decade. Based on multiple parameters, such as historical sales, future competition from other biologics and biosimilars, as well as impending patent expiries, we have provided informed estimates on the financial evolution of the market for the period 2020-2030. It further includes sales-based forecasts of 60+ top selling biologics. The report also provides details on the likely distribution of the current and forecasted opportunity across type of biologic (monoclonal antibody, hormone, enzyme, fusion protein, interferon, gene therapy and others) and key players. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Contents
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the top selling biologics market and its likely evolution in the short-midterm and long term.
Chapter 3 chapter features an overview of biological drugs, highlighting the different types of therapeutic molecules and types of biologics presently available in the market. Further, it includes a brief discussion on the regulatory considerations and biosimilar competition established for biologics.
Chapter 4 presents a detailed assessment of the current market landscape of top selling biologics, along with information on developers (such as year of establishment, company size, location of headquarters and current portfolio of top selling biologics), type of biologic, route of administration, target gene / antigen, type of packaging format, disease indication and target therapeutic area.It also provides an in-depth analysis of key therapeutic areas, such as oncological disorders, metabolic disorders, autoimmune disorders, gastrointestinal disorders, ophthalmic disorders, CNS / neurological disorders, cardiovascular disorders, blood disorders, respiratory disorders, bone disorders and others, in companies that are engaged in the development of top selling biologics.
Chapter 5 includes detailed analysis of revenues generated by top selling biologics (60+) between 2016 and 2020. It includes information on reasons for significant increase / decrease in their sales in the given time span. It also includes the analysis of revenues generated by top selling biologics in 2020, based on several relevant parameters, such as type of biologic and developer.
Chapter 6 features an analysis of the completed, ongoing and planned clinical studies for top selling biologics. The trials considered in the analysis were analyzed based on several relevant parameters, such as trial registration year, trial recruitment status, enrolled patient population, study design, target therapeutic area, geographical location of trials and leading organizations. It is worth highlighting that these studies were registered to evaluate the already approved top selling biologics for potential combinations, device evaluations and comparisons.
Chapter 7 includes detailed analysis on the key promotional strategies that are being / have been adopted by developers of top selling biologics. It further includes a detailed Harvey ball analysis highlighting the extent of promotional content on product websites of all biologics (60+) that fall into this criterion. Additionally, it features detailed profiles, presenting promotional strategies implemented for top 7 blockbuster biologics (in terms of revenues), along with information on their promotional content on product websites (covering key messages for patients and healthcare professionals), details of patient support programs and a brief section on DTC advertisements.
Chapter 8 includes a brief analysis of the product lifecycle management strategies, such as geographical expansion, approval for additional disease indications, reformulations, combination therapies, exploiting alternate routes of administration, reimbursement programs, and pricing strategies, that have been adopted by stakeholders engaged in the development of top selling biologics, during the period 2016-2020. The information in detail has been provided for top 10 biologics (in terms of revenues).
Chapter 9 includes an elaborate analysis representing annual treatment cost of top selling biologics. It includes grid representations, providing information on 60+ top selling biologics, based on type of biologic and target therapeutic area (oncological disorders, metabolic disorders, autoimmune disorders, gastrointestinal disorders, ophthalmic disorders, CNS / neurological disorders, cardiovascular disorders, blood disorders, respiratory disorders, bone disorders and others).
Chapter 10 provides information on the biosimilars for top selling biologics, including information on current status and geography approvals. In addition, it also provides information on biosimilar developers including year of establishment, distribution network and location of headquarter of companies.
Chapter 11 provides existing market size and future growth potential within the top selling biologics market, over the coming decade. It includes sales-based forecasts of 60+ top selling biologics. The report also provides details on the likely distribution of the current and forecasted opportunity across type of biologic (monoclonal antibody, hormone, enzyme, fusion protein, interferon, gene therapy and others) and players. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 12 is a summary of the overall report. It includes key takeaways related to research and analysis from the report in an infographic format.
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which provides list of companies and organizations highlighted in this report.
Table Of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Therapeutic Molecules
3.3. Biologics
3.3.1. Type of Biologics
3.3.1.1. Peptides
3.3.1.2. Monoclonal Antibodies
3.3.1.3. Gene Therapies
3.3.1.4. Growth Factors
3.3.1.5. Hormones
3.3.1.6. Enzymes
3.3.1.7. Vaccines
3.3.1.8. Blood and Related Products
3.3.2. Regulatory Considerations
3.3. Competition from Biosimilars
3.4. Key Market Drivers and Associated Trends
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Top Selling Biologics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Number of Top Selling Biologics
4.3. Top Selling Biologics: Market Landscape
4.3.1. Analysis by Type of Biologic
4.3.2. Analysis by Route of Administration
4.3.3. Analysis by Target Antigen / Gene
4.3.4. Analysis by Type of Biologic and Route of Administration
4.3.5. Analysis by Type of Biologic and Target Antigen / Gene
4.4. Information on Dose Strength and Type of Packaging
4.5. Top Selling Biologics: Key Disease Indications
4.5.1. Analysis by Key Indications
4.6.1 Top Selling Biologics: Target Therapeutic Areas
4.6.2. Analysis by Type of Oncological Disorder
4.6.3. Analysis by Type of Metabolic Disorder
4.6.3.1. Analysis by Type of Autoimmune Disorder
4.6.3.2. Analysis by Type of Gastrointestinal Disorder
4.6.3.3. Analysis by Type of Ophthalmic Disorder
4.6.3.4. Analysis by Type of CNS / Neurological Disorder
4.6.3.5. Analysis by Type of Cardiovascular Disorder
4.6.3.6. Analysis by Type of Blood Disorder
4.6.3.7. Analysis by Type of Respiratory Disorder
4.6.3.8. Analysis by Type of Bone Disorder
5. GLOBAL SALES ANALYSIS OF TOP SELLING BIOLOGICS
5.1. Chapter Overview
5.2. Top Selling Biologics: Global Sales (2020)
5.2.1. Analysis of Global Sales by Type of Biologic
5.2.2. Analysis of Global Sales by Developer
5.2.3. Genentech / Roche: Portfolio of Top Selling Biologics
5.2.3.1. Genentech / Roche: Historical sales of Top Selling Enzymes
5.2.3.2. Genentech / Roche: Historical sales of Top Selling Monoclonal Antibodies
5.2.3.3. Genentech / Roche: Historical sales of Top Selling Hormones
5.2.3.4. Genentech / Roche: Historical sales of Top Selling Other Biologics
5.2.4. AbbVie: Portfolio of Top Selling Biologics
5.2.4.1. AbbVie: Historical sales of Top Selling Monoclonal Antibodies
5.2.4.2. AbbVie: Historical sales of Top Selling Fusion Proteins
5.2.5. Janssen Biotech / Johnson & Johnson: Portfolio of Top Selling Biologics
5.2.5.1. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Monoclonal Antibodies
5.2.5.2. Janssen Biotech / Johnson & Johnson: Historical sales of Top Selling Hormones
5.2.6. Merck: Portfolio of Top Selling Biologics
5.2.6.1. Merck: Historical sales of Top Selling Hormones
5.2.6.2. Merck: Historical sales of Top Selling Monoclonal Antibodies
5.2.6.3. Merck: Historical sales of Top Selling Vaccines
5.2.7. Amgen: Portfolio of Top Selling Biologics
5.2.7.1. Amgen: Historical sales of Top Selling Monoclonal Antibodies
5.2.7.2. Amgen: Historical sales of Top Selling Hormones
5.2.7.3. Amgen: Historical sales of Top Selling Hormones
5.2.8. Eli Lilly: Portfolio of Top Selling Biologics
5.2.8.1. Eli Lilly: Historical sales of Top Selling Monoclonal Antibodies
5.2.8.2. Eli Lilly: Historical sales of Top Selling Hormones
5.2.8.3. Eli Lilly: Historical sales of Top Selling Fusion Proteins
5.2.9. Sanofi: Portfolio of Top Selling Biologics
5.2.9.1. Sanofi: Historical sales of Top Selling Monoclonal Antibodies
5.2.9.2. Sanofi: Historical sales of Top Selling Enzymes
5.2.9.3. Sanofi: Historical sales of Top Selling Hormones
5.2.10. Bristol Myers Squibb: Portfolio of Top Selling Biologics
5.2.10.1. Bristol Myers Squibb: Historical sales of Top Selling Monoclonal Antibodies
5.2.10.2. Bristol Myers Squibb: Historical sales of Top Selling Fusion Proteins
5.2.11. Novo Nordisk: Portfolio of Top Selling Biologics
5.2.11.1. Novo Nordisk: Historical sales of Top Selling Hormones
5.2.12. Novartis: Portfolio of Top Selling Biologics
5.2.12.1. Novartis: Historical sales of Top Selling Monoclonal Antibodies
5.2.13. Alexion Pharmaceuticals: Portfolio of Top Selling Biologics
5.2.13.1. Alexion Pharmaceuticals: Historical sales of Top Selling Monoclonal Antibodies
5.2.13.2. Alexion Pharmaceuticals: Historical sales of Top Selling Enzymes
5.2.14. AstraZeneca: Portfolio of Top Selling Biologics
5.2.14.1. AstraZeneca: Historical sales of Top Selling Monoclonal Antibodies
5.2.15. Biogen: Portfolio of Top Selling Biologics
5.2.15.1. Biogen: Historical sales of Top Selling Monoclonal Antibodies
5.2.15.2. Biogen: Historical sales of Top Selling Gene Therapy
5.2.16. UCB: Portfolio of Top Selling Biologics
5.2.16.1. UCB: Historical sales of Top Selling Monoclonal Antibodies
5.2.17. GlaxoSmithKline: Portfolio of Top Selling Biologics
5.2.17.1. GlaxoSmithKline: Historical sales of Top Selling Monoclonal Antibodies
5.2.18. Biomarin: Portfolio of Top Selling Biologics
5.2.18.1. Biomarin: Historical sales of Top Selling Enzymes
5.2.19. Bayer: Portfolio of Top Selling Biologics
5.2.19.1. Bayer: Historical sales of Top Selling Interferons
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Top Selling Biologics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Recruitment Status
6.3.3. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.4. Analysis by Study Design
6.3.5. Analysis by Patient Segment
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Leading Organizations: Analysis by Number of Registered Trials
6.3.8. Analysis by Target Therapeutic Area
6.3.9. Analysis by Key Biologics
7. PROMOTIONAL ANALYSIS
7.1. Context and Background
7.2. Top Selling Biologics: Product Website Analysis
7.3. Top Selling Biologics: Patient Support-related Services Provided for Top Selling Biologics
7.4. Humira®: Promotional Analysis
7.4.1. Product Website Analysis
7.4.1.1. Messages for Healthcare Professionals
7.4.1.2. Messages for Patients
7.4.1.3. Informative Downloads
7.4.2. Patient Support Services
7.4.3. Advertisements
7.5. Keytruda®: Promotional Analysis
7.5.1. Product Website Analysis
7.5.1.1. Messages for Healthcare Professionals
7.5.1.2. Messages for Patients
7.5.1.3. Informative Downloads
7.5.2. Patient Support Services
7.5.3. Advertisements
7.6. Opdivo®: Promotional Analysis
7.6.1. Product Website Analysis
7.6.1.1. Messages for Healthcare Professionals
7.6.1.2. Messages for Patients
7.6.1.3. Informative Downloads
7.6.2. Patient Support Services
7.6.3. Advertisements
7.7. Avastin®: Promotional Analysis
7.7.1. Product Website Analysis
7.7.1.1. Messages for Healthcare Professionals
7.7.1.2. Messages for Patients
7.7.1.3. Informative Downloads
7.7.2. Patient Support Services
7.8. Rituxan®: Promotional Analysis
7.8.1. Product Website Analysis
7.8.1.1. Messages for Healthcare Professionals
7.8.1.2. Messages for Patients
7.8.1.3. Informative Downloads
7.8.2. Patient Support Services
7.9. Stelara®: Promotional Analysis
7.9.1. Product Website Analysis
7.9.1.1. Messages for Healthcare Professionals
7.9.1.2. Messages for Patients
7.9.1.3. Informative Downloads
7.9.2. Patient Support Services
7.9.3 Advertisements
7.10. Herceptin: Promotional Analysis
7.10.1. Product Website Analysis
7.10.1.1. Messages for Healthcare Professionals
7.10.1.2. Messages for Patients
7.10.1.3. Informative Downloads
7.10.2. Patient Support Services
7.11. Enbrel: Promotional Analysis
7.11.1. Product Website Analysis
7.11.1.1. Messages for Healthcare Professionals
7.11.1.2. Messages for Patients
7.11.1.3. Informative Downloads
7.11.2. Patient Support Services
7.11.3. Advertisements
8. PRODUCT LIFECYCLE MANAGEMENT STRATEGIES
8.1. Introduction
8.2. Key LCM Strategies
8.2.1. Geographical Expansion
8.2.2. Approval for Additional Disease Indications
8.2.3. Reformulations
8.2.4. Combination Therapies
8.2.5. Exploiting Alternate Routes of Administration
8.2.6. Reimbursement Programs
8.2.6.1. Humira®
8.2.6.2. Keytruda®
8.2.6.3. Opdivo®
8.2.6.4. Avastin®
8.2.6.5. Rituxan®
8.2.6.6. Stelara®
8.2.6.7. Herceptin®
8.2.6.8. Enbrel®
8.2.6.9 Remicade®
8.2.6.10 Trulicity®
8.2.7. Pricing Strategies
8.2.7.1. Humira®
8.2.7.2. Keytruda®
8.2.7.3. Opdivo®
8.2.7.4. Avastin®
8.3. Concluding Remarks
9. COST PRICE ANALYSIS
9.1. Chapter Overview
9.2. Factors Contributing to the Price of Biologics
9.3. Annual Treatment Cost of Top Selling Biologics
9.3.1. Price Comparison across Target Therapeutic Areas
9.3.1.1. Oncological Disorders
9.3.1.2. Metabolic Disorders
9.3.1.3. Autoimmune Disorders
9.3.1.4. Gastrointestinal Disorders
9.3.1.5. Ophthalmic Disorders
9.3.1.6. CNS / Neurological Disorders
9.3.1.7. Cardiovascular Disorders
9.3.1.8. Blood Disorders
9.3.1.9. Respiratory Disorders
9.3.1.10. Bone Disorders
9.4 Concluding Remarks
10. BIOSIMILARS
10.1. Chapter Overview
10.2. Introduction to Biosimilars
10.3. Need For Biosimilars
10.4. Biosimilars of Top Selling Biologics
10.4.1. Analysis by Highest Phase of Development
10.4.2. Analysis by Geography
10.4.3. Biosimilar of Top Selling Biologics: Developers Landscape
10.4.3.1. Analysis by Distribution Network
10.4.3.2. Analysis by Location of Headquarters
10.5. Biosimilars VS Top Selling Biologics
10.5.1. Manufacturing
1.5.2. Clinical Trials
10.2.3. Marketing
10.5.4. Safety
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Key Assumptions and Forecast Methodology
11.4. Global Top Selling Biologics Market, 2021-2030
11.4.1. Top Selling Biologics Market: Distribution by Type of Biologic, 2021-2030
11.4.2. Top Selling Biologics Market: Distribution by Key Players, 2021-2030
11.5. Top Selling Biologics Market: Product-wise Sales Forecast
11.3. Top Selling Biologics: Product Wise Forecast
11.3.1. Monoclonal Antibodies
11.3.1.1. Actemra®
11.3.1.2. Avastin®
11.3.1.3. Benlysta®
11.3.1.4. Cosentyx®
11.3.1.5. Cyramza®
11.3.1.6. Darzalex®
11.3.1.7. Dupixent®
11.3.1.8. Erbitux®
11.3.1.9. Fasenra®
11.3.1.10. Gazyva®
11.3.1.11. Hemlibra®
11.3.1.12. Herceptin®
11.3.1.13. Humira®
11.3.1.14. Ilaris®
11.3.1.15. Imfinzi®
11.3.1.16. Keytruda®
11.3.1.17. Lucentis®
11.3.1.18. Nucala®
11.3.1.19. Ocrevus™
11.3.1.20. Opdivo®
11.3.1.21. Perjeta®
11.3.1.22. Prolia®
11.3.1.23. Remicade®
11.3.1.24. Repatha®
11.3.1.25. Rituxan®
11.3.1.26. Soliris®
11.3.1.27. Stelara®
11.3.1.28. Synagis®
11.3.1.29. Taltz®
11.3.1.30. Tecentriq®
11.3.1.31. Tremfya®
11.3.1.32. Tysabri®
11.3.1.33. Vectibix®
11.3.1.34. Xgeva®
11.3.1.35. Xolair®
11.3.1.36. Yervoy®
11.3.2. Hormones
11.3.2.1. Forteo®
11.3.2.2. Gonal-f®
11.3.2.3. Humalog®
11.3.2.4. Humulin®
11.3.2.5. Lantus®
11.3.2.6. Levemir®
11.3.2.7. Mircera®
11.3.2.8. Neulasta®
11.3.2.9. Novolog®
11.3.2.10. Procrit / Eprex®
11.3.2.11. Toujeo®
11.3.2.12. Tresiba®
11.3.2.13. Victoza®
11.3.3. Enzymes
11.3.3.1. Activase®
11.3.3.2. Fabrazyme®
11.3.3.3. Myozyme®
11.3.3.4. Pulmozyme®
11.3.3.5. Strensiq®
11.3.3.6. Vimizim®
11.3.4. Fusion Proteins
11.3.4.1. Aranesp®
11.3.4.2. Botox®
11.3.4.3. Enbrel®
11.3.4.4. Epogen®
11.3.4.5. Orencia®
11.3.4.6. Trulicity®
11.3.5. Interferons
11.3.5.1. Avonex / Rebif®
11.3.5.2. Betaseron®
11.3.5.3. Kadcyla®
11.3.6. Gene therapies
11.3.6.1. Spinraza®
11.3.7. Antibody fragments
11.3.7.1. Cimzia®
11.3.8. Vaccines
11.3.8.1. Varivax®
12. CONCLUSION
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Types of Biologically Derived Therapeutics
Figure 3.2. Stages of the Biomanufacturing Process
Figure 3.3. Comparison of FDA Approval Process for Small Molecules and Biologics
Figure 4.1. Developers of Top Selling Biologics: Distribution by Year of Establishment
Figure 4.2. Developers of Top Selling Biologics: Distribution by Company Size
Figure 4.3. Developers of Top Selling Biologics: Distribution by Location of Headquarters
Figure 4.5. Developers of Top Selling Biologics: Distribution by Number of Top Selling Biologics
Figure 4.6. Top Selling Biologics: Distribution by Type of Biologic
Figure 4.7. Logo Landscape: Distribution of Developers by Type of Biologic
Figure 4.8. Top Selling Biologics: Distribution by Route of Administration
Figure 4.9. Top Selling Biologics: Distribution by Target Antigen / Gene
Figure 4.10. Top Selling Biologics: Distribution by Type of Biologic and Route of Administration
Figure 4.11. Top Selling Biologics: Distribution by Type of Biologic and Target Antigen / Gene
Figure 4.12. Top Selling Biologics: Distribution by Type of Packaging Format
Figure 4.13. Top Selling Biologics: Distribution by Key Disease Indication
Figure 4.14. Top Selling Biologics: Distribution by Target Therapeutic Area
Figure 4.15. Top Selling Biologics: Distribution by Type of Oncological Disorder
Figure 4.16. Top Selling Biologics: Distribution by Type of Metabolic Disorder
Figure 4.17. Top Selling Biologics: Distribution by Type of Autoimmune Disorder
Figure 4.18. Top Selling Biologics: Distribution by Type of Gastrointestinal Tract Disorder
Figure 4.19. Top Selling Biologics: Distribution by Type of Ophthalmic Disorder
Figure 4.20. Top Selling Biologics: Distribution by Type of CNS / Neurological Disorder
Figure 4.21. Top Selling Biologics: Distribution by Type of Cardiovascular Disorder
Figure 4.22. Top Selling Biologics: Distribution by Type of Blood Disorder
Figure 4.23. Top Selling Biologics: Distribution by Type of Respiratory Disorder
Figure 4.24. Top Selling Biologics: Distribution by Type of Bone Disorder
Figure 5.1. Top Selling Biologics: Distribution of Global Sales by Type of Biologic
Figure 5.2. Top Selling Biologics: Distribution of Global Sales by Route of Administration, 2020 (USD Million)
Figure 5.3. Top Selling Biologics: Distribution of Global Sales by Therapeutic Area, 2020 (USD Million)
Figure 5.4. Top Selling Biologics: Distribution of Global Sales by Developer, 2020 (USD Million)
Figure 5.5. Genentech / Roche: Year-wise Trend of Sales Generated by Top Selling Enzymes
Figure 5.6. Genentech / Roche: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.7. Genentech / Roche: Year-wise Trend of Sales Generated by Top Selling Interferons
Figure 5.8. AbbVie: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.9. AbbVie: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins
Figure 5.10. Janssen Biotech / Johnson & Johnson: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.11. Janssen Biotech / Johnson & Johnson: Year-wise Trend of Sales Generated by Top Selling Hormones
Figure 5.12. Merck: Year-wise Trend of Sales Generated by Top Selling Hormones
Figure 5.13. Merck: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.14. Merck: Year-wise Trend of Sales Generated by Top Selling Vaccines
Figure 5.15. Amgen: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.16. Amgen: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins
Figure 5.17. Amgen: Year-wise Trend of Sales Generated by Top Selling Hormones
Figure 5.18. Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.19. Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Hormones
Figure 5.20. Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins
Figure 5.21. Sanofi: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.22. Sanofi: Year-wise Trend of Sales Generated by Top Selling Enzymes
Figure 5.23. Sanofi: Year-wise Trend of Sales Generated by Top Selling hormones
Figure 5.24. Bristol Myers Squibb: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.25. Bristol Myers Squibb: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins
Figure 5.26. Novo Nordisk: Year-wise Trend of Sales Generated by Top Selling Hormones
Figure 5.27. Novartis: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.28. Alexion Pharmaceuticals: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.29. Alexion Pharmaceuticals: Year-wise Trend of Sales Generated by Top Selling Enzymes
Figure 5.30. AstraZeneca: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.31. Biogen: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.32. Biogen: Year-wise Trend of Sales Generated by Top Selling Interferons
Figure 5.33. Biogen: Year-wise Trend of Sales Generated by Top Selling Gene Therapies
Figure 5.34. UCB: Year-wise Trend of Sales Generated by Top Selling Antibody Fragments
Figure 5.35. GlaxoSmithKline: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies
Figure 5.36. BioMarin: Year-wise Trend of Sales Generated by Top Selling Enzymes
Figure 5.37. Bayer: Year-wise Trend of Sales Generated by Top Selling Interferons
Figure 6.1. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.2. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016 - 2020 (Till September)
Figure 6.3. Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2016 - 2020 (Till September)
Figure 6.4. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 6.5. Clinical Trial Analysis: Distribution by Study Design
Figure 6.6. Clinical Trial Analysis: Distribution by Patient Segment
Figure 6.7. Clinical Trial Analysis: Geographical Distribution of Trials
Figure 6.8. Leading Organizations: Distribution by Number of Trials
Figure 6.9. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 6.10. Most Prominent Biologics: Analysis by Number of Clinical Trials
Figure 7.1. Product Website Analysis: Top Selling Biologics
Figure 7.2. Humira®, Website Analysis: Messages for Healthcare Professionals
Figure 7.3. Humira®, Website Analysis: Messages for Patients
Figure 7.4. Humira®: Patient Support Services
Figure 7.5. Humira®: TV Commercials
Figure 7.6. Keytruda®, Website Analysis: Messages for Healthcare Professionals
Figure 7.7. Keytruda®, Website Analysis: Messages for Patients
Figure 7.8. Keytruda®, Patient Support Services
Figure 7.9. Keytruda®: TV Commercials
Figure 7.10. Opdivo®, Website Analysis: Messages for Healthcare Professionals
Figure 7.11. Opdivo®, Website Analysis: Messages for Patients
Figure 7.12. Opdivo®: Patient Support Services
Figure 7.13. Opdivo®: TV Commercials
Figure 7.14. Avastin®, Website Analysis: Messages for Healthcare Professionals
Figure 7.15. Avastin®, Website Analysis: Messages for Patients
Figure 7.16. Avastin®: Patient Support Services
Figure 7.17. Rituxan®, Website Analysis: Messages for Healthcare Professionals
Figure 7.18. Rituxan®, Website Analysis: Messages for Patients
Figure 7.19. Rituxan®: Patient Support Services
Figure 7.20. Stelara®, Website Analysis: Messages for Healthcare Professionals
Figure 7.21. Stelara®, Website Analysis: Messages for Patients
Figure 7.22. Stelara®: Patient Support Services
Figure 7.23. Stelara®: TV Commercials
Figure 7.24. Herceptin®, Website Analysis: Messages for Healthcare Professionals
Figure 7.25. Herceptin®, Website Analysis: Messages for Patients
Figure 7.26. Herceptin®: Patient Support Services
Figure 7.27. Enbrel®, Website Analysis: Messages for Healthcare Professionals
Figure 7.28. Enbrel®, Website Analysis: Messages for Patients
Figure 7.29. Enbrel®: Patient Support Services
Figure 7.30. Enbrel®: TV Commercials
Figure 8.1. Product Life Cycle Management Strategies for Top Selling Biologics: Geographical Expansion
Figure 8.2. Product Life Cycle Management Strategies for Top Selling Biologics: New Indication Approvals, 2016-2020
Figure 8.3. Product Life Cycle Management Strategies for Top Selling Biologics: New Drug Delivery systems
Figure 8.4. Harvey Ball Analysis: Key LCM Strategies based on Adoption
Figure 9.1. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Oncological Disorders
Figure 9.2. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Metabolic Disorders
Figure 9.3. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Gastrointestinal Disorders
Figure 9.4. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for CNS / Neurological Disorders
Figure 9.5. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Cardiovascular Disorders
Figure 9.6. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Bone Disorders
Figure 9.7. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Blood Disorders
Figure 9.8. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Respiratory Disorders
Figure 9.9. Comparative Grid Representation: Annual Treatment Cost of Top Selling Biologics for Autoimmune Disorders
Figure 10.1. Biosimilars of Top Selling Biologics: Distribution by Highest Phase of Development
Figure 10.2. Biosimilars of Top Selling Biologics: Distribution by Geography
Figure 10.4. Biosimilars of Top Selling Biologics Developer Landscape: Distribution by
Figure 10.5. Biosimilars of Top Selling Biologics Developer Landscape: Distribution by Location of Headquarters
Figure 11.1. Global Top Selling Biologics Market, 2020-2030 (USD Million)
Figure 11.2. Top Selling Biologics Market: Distribution by Type of Biologic, 2021-2030
Figure 11.3. Top Selling Biologics Market: Distribution by Key Players, 2021-2030
Figure 11.5. Humira® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.6. Keytruda® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.7. Rituxan® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.8. Herceptin® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.9. Avastin® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.10. Lucentis® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.11. Lantus® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.12. Enbrel® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.13. Remicade® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.14. Neulasta® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.15. Avonex / Rebif® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.16. Stelara® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.17. Victoza® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.18. Botox® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.19. Soliris® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.20. Humalog® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.21. Xolair® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.22. Novolog® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.23. Orencia® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.24 Cosentyx® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.25 Perjeta® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.26 Prolia® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.27. Aranesp® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.28. Opdivo® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.29. Ocrevus™ Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.30. Darzalex® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.31. Cimzia® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.32. Synagis® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.33. Yervoy® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.34. Kadcyla® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.35. Activase® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.36. Epogen® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.37. Activase® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.38. Betaseron® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.39. Tremfya® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.40. Dupixent® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.41. Taltz® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.42. Dupixent® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.43. Nucala® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.44. Tresiba® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.45. Toujeo® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.46. Xgeva® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.47. Ilaris® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.48. Levemir® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.49. Forteo® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.50. Gonal-f® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.51. Varivax® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.52. Humulin® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.53. Repatha® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.54. Actemra® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.55. Gazyva® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.56. Tecentriq® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.57. Hemlibra® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.58. Imfinzi® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.59. Spinraza® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.60. Procrit / Eprex® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.61. Fabrazyme® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.62. Erbitux® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.63. Tysabri® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.64. Myozyme® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.65. Vectibix® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.66. Mircera® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.67. Benlysta® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.68. Cyramza® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.69. Fasenra® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.70. Vimizim® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.71. Strensiq® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.72. Pulmozyme® Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 3.1 Comparison of Key Characteristics of Small Molecules and Biologics
Table 3.2 List of Biosimilars Marketed in the US
Table 4.1 Developers of Top Selling Biologics: Information on Year of Establishment, Company Size, Location of Headquarters, and Top Selling Biologics
Table 4.2 Top Selling Biologics: Top Selling Biologics: Information on Developer(s), Type of Biologic, Route of Administration and Target Gene / Antigen
Table 4.3 Top Selling Biologics: Information on Available Packaging Formats
Table 4.4 Top Selling Biologics: Information on Dose Strength (Vial)
Table 4.5 Top Selling Biologics: Information on Dose Strength (Prefilled Syringe)
Table 4.6 Top Selling Biologics: Information on Dose Strength (Pen / Prefilled Pen)
Table 4.7 Top Selling Biologics: Information on Dose Strength (Autoinjector)
Table 4.8 Top Selling Biologics: Information on Dose Strength (Others)
Table 4.9 Top Selling Biologics: Information on Key Disease Indications
Table 5.1. Top Selling Biologics: Information on Developer(s), Type of Biologic, Route of Administration, Therapeutic Area and Global Sales (2020)
Table 7.1. Top Selling Biologics: Patient Support Services
Table 8.1. Top Selling Biologics: Reformulations, 2016-2020
Table 8.2. Top Selling Biologics: Combination Therapies, 2016- 2020
Table 9.1. List of Top Selling Biologics Approved for Oncological Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.2. List of Top Selling Biologics Approved for Metabolic Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.3. List of Top Selling Biologics Approved for Gastrointestinal Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.4. List of Top Selling Biologics Approved for CNS / Neurological Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.5. List of Top Selling Biologics Approved for Cardiovascular Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.6. List of Top Selling Biologics Approved for Bone Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.7. List of Top Selling Biologics Approved for Blood Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.8. List of Top Selling Biologics Approved for Respiratory Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 9.9. List of Top Selling Biologics Approved for Autoimmune Disorders: Information on Type of Biologic and Annual Treatment Cost
Table 10.1. Biosimilars for Top Selling Biologics: Information on Reference Biologic, Year of Establishment, Geography, Highest Phase of Development and Type of Distribution Network
Table 12.1. Top Selling Biologics: Concluding Remarks
Table 13.1 Developers of Top Selling Biologics: Distribution by Year of Establishment
Table 13.2 Developers of Top Selling Biologics: Distribution by Company Size
Table 13.3 Developers of Top Selling Biologics: Distribution by Location of Headquarters
Table 13.4 Developer Landscape: Distribution by Number of Top Selling Biologics
Table 13.5 Top Selling Biologics: Distribution by Type of Biologic
Table 13.6 Top Selling Biologics: Distribution by Route of Administration
Table 13.7 Top Selling Biologics: Distribution by Target Antigen / Gene
Table 13.8 Top Selling Biologics: Distribution by Packaging Formats
Table 13.9 Top Selling Biologics: Distribution by Key Indications
Table 13.10 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 13.11 Top Selling Biologics: Distribution by Oncological Disorders
Table 13.12 Top Selling Biologics: Distribution by Metabolic Disorders
Table 13.13 Top Selling Biologics: Distribution by Autoimmune Disorders
Table 13.14 Top Selling Biologics: Distribution by Gastrointestinal Disorders
Table 13.15 Top Selling Biologics: Distribution by Ophthalmic Disorders
Table 13.16 Top Selling Biologics: Distribution by CNS / Neurological Disorders
Table 13.17 Top Selling Biologics: Distribution by Cardiovascular Disorders
Table 13.18 Top Selling Biologics: Distribution by Blood Disorders
Table 13.19 Top Selling Biologics: Distribution by Respiratory Disorders
Table 13.20 Top Selling Biologics: Distribution by Bone Disorders
Table 13.21 Top Selling Biologics: Distribution of Global Sales (2020) by Type of Biologic (USD Million)
Table 13.22 Top Selling Biologics : Distribution of Global Sales (2020) by Route of Administration (USD Million)
Table 13.23 Top Selling Biologics: Distribution of Global Sales (2020) by Therapeutic Area (USD Million)
Table 13.24 Top Selling Biologics: Distribution of Global Sales (2020) by Developer (USD Million)
Table 13.25 Genentech / Roche: Year-wise Trend of Sales Generated by Top Selling Enzymes (USD Million)
Table 13.26 Genentech: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.27 Genentech / Roche: Year-wise Trend of Sales Generated by Top Selling Interferons (USD Million)
Table 13.28 AbbVie: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.29 AbbVie: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins (USD Million)
Table 13.30 Janssen Biotech / Johnson & Johnson: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.31 Janssen Biotech / Johnson & Johnson: Year-wise Trend of Sales Generated by Top Selling Hormones (USD Million)
Table 13.32 Merck: Year-wise Trend of Sales Generated by Top Selling Hormones (USD Million)
Table 13.33 Merck: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million
Table 13.34 Merck: Year-wise Trend of Sales Generated by Top Selling Vaccines (USD Million)
Table 13.35 Amgen: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.36 Amgen: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins (USD Million)
Table 13.37 Amgen: Year-wise Trend of Sales Generated by Top Selling Hormones (USD Million)
Table 13.38 Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.39 Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Hormones (USD Million)
Table 13.40 Eli Lilly: Year-wise Trend of Sales Generated by Top Selling Fusion Proteins (USD Million)
Table 13.41 Sanofi: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.42 Sanofi: Year-wise Trend of Sales Generated by Top Selling Enzymes (USD Million)
Table 13.43 Sanofi: Year-wise Trend of Sales Generated by Top Selling hormones (USD Million)
Table 13.44 Bristol Myers Squibb: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.45 Bristol Myers Squibb: Year-wise Trend of Sales Generated by Top Selling Fusion proteins (USD Million)
Table 13.46 Novo Nordisk: Year-wise Trend of Sales Generated by Top Selling Hormones (USD Million)
Table 13.47 Novartis: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.48 Alexion Pharmaceuticals: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.49 Alexion Pharmaceuticals: Year-wise Trend of Sales Generated by Top Selling Enzymes (USD Million)
Table 13.50 AstraZeneca: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.51 Biogen: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.52 Biogen: Year-wise Trend of Sales Generated by Top Selling Interferon (USD Million)
Table 13.53 Biogen: Year-wise Trend of Sales Generated by Top Selling Gene therapy (USD Million)
Table 13.54 UCB: Year-wise Trend of Sales Generated by Top Selling Antibody Fragment (USD Million)
Table 13.55 GlaxoSmithKline: Year-wise Trend of Sales Generated by Top Selling Monoclonal Antibodies (USD Million)
Table 13.56 Biomarin: Year-wise Trend of Sales Generated by Top Selling Enzyme (USD Million)
Table 13.57 Bayer: Year-wise Trend of Sales Generated by Top Selling Interferon (USD Million)
Table 13.58 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 13.59 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-Post-2020 (Till September)
Table 13.60 Clinical Trial Analysis: Distribution of patients Enrolled by Trial Registration Year
Table 13.61 Clinical Trial Analysis: Distribution by Study Design
Table 13.62 Clinical Trial Analysis: Distribution by Patient Segment
Table 13.63 Clinical Trial Analysis: Geographical Distribution of Trials
Table 13.64 Leading Organizations: Analysis by Number of Trials
Table 13.65 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 13.66 Clinical Trial Analysis: Analysis by Number of Clinical Trials Per Drug
Table 13.67 Top Selling Biologics Biosimilars: Distribution by Status
Table 13.68 Top Selling Biologics Biosimilars: Distribution by Geography Approvals
Table 13.71 Top Selling Biologics: Overall Top Selling Biologics Market, 2021-2030
Table 13.72 Top Selling Biologics: Distribution by Type of Biologic
Table 13.73 Top Selling Biologics: Distribution by Key Players
Table 13.74 Actemra Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.75 Avastin Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.76 Benlysta Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.77 Cosentyx Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.78 Cyramza Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.79 Darzalex Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.80 Dupixent Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.81 Erbitux Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.82 Fasenra Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.83 Gazyva Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.84 Hemlibra Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.85 Herceptin Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.86 Humira Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.87 Ilaris Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.88 Imfinzi Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.89 Keytruda Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.90 Lucentis Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.91 Nucala Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.92 Ocrevus Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.93 Opdivo Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.94 Perjeta Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.95 Prolia Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.96 Remicade Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.97 Repatha Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.98 Rituxan Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.99 Soliris Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.100 Stelara Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.101 Synagis Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.102 Taltz Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.103 Tecentriq Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.104 Tremfya Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.105 Tysabri Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.106 Vectibix Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.107 Xgeva Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.108 Xolair Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.109 Yervoy Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.110 Forteo Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.111 Gonal-f Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.112 Humalog Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.113 Humulin Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.114 Lantus Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.115 Levemir Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.116 Mircera Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.117 Neulasta Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.118 Novolog Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.119 Procrit / Eprex Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.120 Tojeo Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.121 Tresiba Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.122 Victoza Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.123 Activase Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.124 Fabrazyme Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.125 Myozyme Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.126 Pulmozyme Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.127 Strensiq Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.128 Vimzim Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.129 Aranesp Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.130 Botox Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.131 Enbrel Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.132 Epogen Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.133 Orencia Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.134 Trulicity Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.135 Avonex / Rebif Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.136 Betaseron Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.137 Kadcyla Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.138 Spinraza Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.139 Cimzia Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 13.140 Varivax Sales Forecast (Till 2030): Base Scenario (USD Million)
The following companies and organizations have been mentioned in the report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES